Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODULATE: IMM-101 + SOC in Metastatic Cancer
NCT03009058Phase 2Terminated
- Sponsor
- Immodulon Therapeutics
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of IMM-101 in pancreatic cancer (PC), colorectal cancer (CRC), cholangiocarcinoma (CCA), lung cancer, melanoma, sponsored by Immodulon Therapeutics. Started May 2017; status: terminated.
02
Drugs
IMM-101
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)cholangiocarcinoma (CCA)lung cancermelanoma
Beyond the preview
Go deeper on NCT03009058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009058.